




The EU regulation on health technology assessment: what's in it and why it matters?"

**HTA information day, Seville
22 November 2023**

*Jose A. VALVERDE, Policy Officer
Directorate-General for Health and Food Safety
European Commission*



HTA domains



Regulatory process vs. HTA



- Single licensing system
- Single EU legislation
- Well defined and agreed assessment criteria



- All Member States have different HTA systems
- National legislations and procedures
- Different methodologies and assessment criteria

Regulatory process vs. HTA



- **Single licensing system**
- **Single EU legislation**
- **Well defined and agreed assessment criteria**




- **Joint framework for clinical assessment**
- **Common methodology and approach for clinical assessments and scientific consultations**



- **Use of joint clinical assessment in national decision-making**
- **Non-clinical assessments**
- **Decision making on pricing and reimbursements**

Strengthening EU HTA cooperation



JA1 (2010 – 2012)
JA2 (2012 – 2015)
JA3 (2016 – 2021)



HTA Regulation

Regulation (EU) 2021/2282 on HTA

- ❖ Adoption 15 December 2021
- ❖ Entry into force 11 January 2022
- ❖ Entry into application 12 January 2025
- ❖ Main objectives: establishing a support framework and procedures for cooperation of Member States on health technologies at Union level; a mechanism for the submission of evidence for joint clinical assessments only once at Union level; common rules and methodologies for joint clinical assessments.

HTA Regulation – Key principles

- **Joint work** on common **scientific, clinical aspects** of HTA
- **Driven by Member State HTA bodies**
- Ensure **high quality, timeliness and transparency**
- Ensure **involvement of stakeholders**
- Ensure **use of joint work in national HTA processes**
- **Member States** remain responsible for:
 - Drawing **conclusions on added value** for their health system
 - Taking **decisions on pricing & reimbursement**
- **Addresses experts and stakeholders' engagement in joint work**
- **Progressive implementation**

Joint HTA activities

Joint Clinical Assessments (JCA) on:

- **medicines** first 3 years: cancer medicines and advanced therapy medicinal products

from January 2028: + orphan medicinal products

from 2030: full scope

- a selection of high-risk medical devices and in-vitro medical devices

Joint Scientific Consultations (JSC)


- in parallel with the European Medicines Agency

Emerging Health Technologies


Methodology for joint HTA work

Voluntary cooperation


Governance



Type of organisations in the HTA Stakeholder Network



Halfway through the preparatory phase



Implementing acts to be adopted by 2025

<ul style="list-style-type: none">• Procedural rules for JCA medicinal products	Q4 2023
<ul style="list-style-type: none">• Procedural rules for the prevention of conflict of interest	Q1 2024
<ul style="list-style-type: none">• Cooperation by exchange of information with the EMA	Q1 2024
<ul style="list-style-type: none">• Procedural rules for JSC medicinal products	Q2 2024
<ul style="list-style-type: none">• Procedural rules for JCA medical devices and IVD medical devices	Q3 2024
<ul style="list-style-type: none">• Procedural rules for JSC medical devices and IVD medical devices	Q4 2024

Preparation, consultation and adoption of implementing acts

Early reflection

The Commission carries out appropriate consultations during its preparatory work.


'Comitology' (examination) procedure

HTA Committee provides **opinion** on the draft text

Targeted consultation
Consultations with relevant stakeholders.

Public consultation
Consultations with all stakeholders on [Have your Say](#) (4-week feedback period)


Collaboration with EMA under the HTA regulation




Collaboration with EMA under the HTA regulation




Life-cycle
evidence
planning




Cross-decision
making
collaboration



Communication
and training



Research
projects and
policy initiatives



Processes
under the
Regulation



Rolling plan regularly updated

IMPLEMENTATION ROLLING PLAN

2023-2024

REGULATION (EU) 2021/2282 ON HEALTH TECHNOLOGY ASSESSMENT

This rolling plan contains a list of key activities that the Commission has carried out or intends to carry out in preparation for the implementation of Regulation 2021/2282 on Health Technology Assessment (the "HTAR"). The plan is subject to regular review to provide national authorities and stakeholders with the most updated information.

The HTAR entered into force on January 11, 2022. It will be applicable as of January 12, 2025.

Latest update: **June 2023**

SUBJECT	LEGAL BASIS	DESCRIPTION	EXPECTED TIMELINE	STATUS
Member State Coordination Group on Health Technology Assessment (HTACG)				
HTAR Article 3				
Fourth meeting of the HTACG	HTAR Article 3		13 June 2023	In preparation
Third meeting of the subgroup on methodological and procedural guidance			6 July 2023	In preparation
Third meeting of the subgroup on Joint Clinical Assessments			7 July 2023	In preparation
Third meeting of the subgroup on Joint Scientific Consultations			6 October 2023	In preparation

https://health.ec.europa.eu/health-technology-assessment_en

Awareness raising – HTA information events

#HealthUnion

FROM THEORY TO PRACTICE:
**Implementing the
EU Health Technology
Assessment Regulation**

nensurial/istock via Getty Images



HAG |  European Commission



Conclusions: Co-creation of a new system

Inclusiveness and transparency as key principles of the joint work

Commitment of all Member States and all stakeholders is essential to secure smooth implementation

16 months left until application

Thank you for your attention

Any question?

Jose.VALVERDE-ALBACETE@ec.europa.eu

Bela.DAJKA@ec.europa.eu

SANTE-HTA@ec.europa.eu

© European Union 2023

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.